Pegcetacoplan differs from other approved PNH therapies as it inhibits the complement system at the level of C3, rather than C5, which acts downstream from C3 (Fig. 5A) [32, 33]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.